Skip to main content

Table 4 Predictive clinical factors of PFS after crizotinib treatment

From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Clinical factors Univariate analysis P value Multivariate analysis
HR 95%CI P value
Gender (male versus female) 0.318
Age 0.175
Smoking history (smoker versus never smoker) 0.255
ECOG score (> = 2 versus 0 or 1) 0.011 2.345 1.137–4.834 0.021
TNM stage (IV versus IIIB) 0.600
BM status (with versus without BM before crzotinib) 0.137
First line treatment (N1-PP versus 1-PP or crizotinib) 0.009 2.335 1.162–4.691 0.017
  1. Note. —Covariates with a P ≤ 0.10 in univariate analysis were included in the multivariate model. Multivariate analysis was performed by using the Cox proportional hazards model